{"transactions":[{"id":2356337,"issuer":{"id":2096,"kind":"organization","name":"NEOGENOMICS INC","symbol":"NEO"},"owners":[{"id":129648,"kind":"person","name":"Mallon Mark","position":1,"cik":"0001763533","reported_name":"Mallon Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2022-03-04T00:59:06.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":347777,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"On March 1, 2022, Mr. Mallon was granted 347,777 stock options. These options vest ratably over the first four anniversary dates of the grant date."}],"balance_after":347777,"derivative":{"exercise_price":21.41,"expiration_date":"2029-03-01","underlying":"Common Stock","underlying_shares":347777},"source":{"system":"sec-edgar","filing":"0001077183-22-000043","document":"wf-form4_164635552579023.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000043/wf-form4_164635552579023.xml","form_type":"4"}},{"id":2356336,"issuer":{"id":2096,"kind":"organization","name":"NEOGENOMICS INC","symbol":"NEO"},"owners":[{"id":129648,"kind":"person","name":"Mallon Mark","position":1,"cik":"0001763533","reported_name":"Mallon Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2022-03-04T00:59:06.000Z","date":"2022-03-01","kind":"grant","acquired":true,"shares":142457,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"On March 1, 2022, Mr. Mallon was granted 142,457 restricted stock awards. These awards vest ratably over the first four anniversary dates of the grant date."}],"balance_after":368051,"source":{"system":"sec-edgar","filing":"0001077183-22-000043","document":"wf-form4_164635552579023.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718322000043/wf-form4_164635552579023.xml","form_type":"4"}},{"id":2456398,"issuer":{"id":2096,"kind":"organization","name":"NEOGENOMICS INC","symbol":"NEO"},"owners":[{"id":129648,"kind":"person","name":"Mallon Mark","position":1,"cik":"0001763533","reported_name":"Mallon Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-30T23:05:03.000Z","date":"2021-12-30","kind":"grant","acquired":true,"shares":152858,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 30, 2021, Mr. Mallon was granted 152,858 restricted stock awards. These awards vest ratably over three years with the first tranche vesting on December 31, 2022."}],"balance_after":225594,"source":{"system":"sec-edgar","filing":"0001077183-21-000278","document":"wf-form4_164090548763134.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718321000278/wf-form4_164090548763134.xml","form_type":"4"}},{"id":2484206,"issuer":{"id":2096,"kind":"organization","name":"NEOGENOMICS INC","symbol":"NEO"},"owners":[{"id":129648,"kind":"person","name":"Mallon Mark","position":1,"cik":"0001763533","reported_name":"Mallon Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-12-06T21:16:42.000Z","date":"2021-12-06","kind":"purchase","acquired":true,"shares":17000,"price":30.63,"value":520710.0,"ownership":{"direct":true},"balance_after":72736,"source":{"system":"sec-edgar","filing":"0001077183-21-000256","document":"wf-form4_163882538985808.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718321000256/wf-form4_163882538985808.xml","form_type":"4"}},{"id":2743374,"issuer":{"id":2096,"kind":"organization","name":"NEOGENOMICS INC","symbol":"NEO"},"owners":[{"id":129648,"kind":"person","name":"Mallon Mark","position":1,"cik":"0001763533","reported_name":"Mallon Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2021-04-21T22:19:59.000Z","date":"2021-04-19","kind":"grant","acquired":true,"shares":151016,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On April 19, 2021, Mr. Mallon was granted 151,016 stock options. These options vest ratably over the first four anniversary dates of the grant date."}],"balance_after":151016,"derivative":{"exercise_price":49.34,"expiration_date":"2028-04-19","underlying":"Common Stock","underlying_shares":151016},"source":{"system":"sec-edgar","filing":"0001077183-21-000111","document":"wf-form4_161904358115470.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718321000111/wf-form4_161904358115470.xml","form_type":"4"}},{"id":2743373,"issuer":{"id":2096,"kind":"organization","name":"NEOGENOMICS INC","symbol":"NEO"},"owners":[{"id":129648,"kind":"person","name":"Mallon Mark","position":1,"cik":"0001763533","reported_name":"Mallon Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Common Stock","published_at":"2021-04-21T22:19:59.000Z","date":"2021-04-19","kind":"grant","acquired":true,"shares":55736,"price":0,"value":0.0,"ownership":{"direct":true},"balance_after":55736,"source":{"system":"sec-edgar","filing":"0001077183-21-000111","document":"wf-form4_161904358115470.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1077183/000107718321000111/wf-form4_161904358115470.xml","form_type":"4"}},{"id":2819848,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":129648,"kind":"person","name":"Mallon Mark","position":1,"cik":"0001763533","reported_name":"Mallon Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A Common Stock","published_at":"2021-03-02T21:37:55.000Z","date":"2021-02-26","kind":"sale","acquired":false,"shares":22582,"price":9.11,"value":205722.02,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 33.33% of the reporting person's restricted stock units granted on February\n27, 2020."}],"balance_after":470605,"source":{"system":"sec-edgar","filing":"0001209191-21-016044","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919121016044/doc4.xml","form_type":"4"}},{"id":2819847,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":129648,"kind":"person","name":"Mallon Mark","position":1,"cik":"0001763533","reported_name":"Mallon Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A Common Stock","published_at":"2021-03-02T21:37:55.000Z","date":"2021-02-26","kind":"sale","acquired":false,"shares":8093,"price":9.11,"value":73727.23,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January 9, 2019."}],"balance_after":493187,"source":{"system":"sec-edgar","filing":"0001209191-21-016044","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919121016044/doc4.xml","form_type":"4"}},{"id":3150760,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":129648,"kind":"person","name":"Mallon Mark","position":1,"cik":"0001763533","reported_name":"Mallon Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A Common Stock","published_at":"2020-05-13T21:21:51.000Z","date":"2020-05-11","kind":"sale","acquired":false,"shares":23206,"price":10.35,"value":240182.1,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. This sale was made to cover tax withholding\nobligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on April 1,\n2019."}],"balance_after":501280,"source":{"system":"sec-edgar","filing":"0001209191-20-028900","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919120028900/doc4.xml","form_type":"4"}},{"id":3238005,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":129648,"kind":"person","name":"Mallon Mark","position":1,"cik":"0001763533","reported_name":"Mallon Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A Common Stock","published_at":"2020-03-02T21:29:44.000Z","date":"2020-02-27","kind":"grant","acquired":true,"shares":221061,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The restricted stock unit award, granted as an annual performance award, vests as to approximately 33.33% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof."}],"balance_after":524486,"source":{"system":"sec-edgar","filing":"0001209191-20-014467","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919120014467/doc4.xml","form_type":"4"}},{"id":3249158,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":129648,"kind":"person","name":"Mallon Mark","position":1,"cik":"0001763533","reported_name":"Mallon Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A Common Stock","published_at":"2020-02-25T21:45:43.000Z","date":"2020-02-24","kind":"sale","acquired":false,"shares":1,"price":11.25,"value":11.25,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.  This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January 9, 2019."}],"balance_after":303425,"source":{"system":"sec-edgar","filing":"0001209191-20-012528","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919120012528/doc4.xml","form_type":"4"}},{"id":3249157,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":129648,"kind":"person","name":"Mallon Mark","position":1,"cik":"0001763533","reported_name":"Mallon Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A Common Stock","published_at":"2020-02-25T21:45:43.000Z","date":"2020-02-21","kind":"sale","acquired":false,"shares":7983,"price":11.63,"value":92842.29,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"This sale was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person.  This sale was made to cover tax withholding obligations in connection with vesting and settlement of approximately 25% of the reporting person's restricted stock units granted on January 9, 2019."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.58 to $11.64, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote."}],"balance_after":303426,"source":{"system":"sec-edgar","filing":"0001209191-20-012528","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919120012528/doc4.xml","form_type":"4"}},{"id":3564607,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":129648,"kind":"person","name":"Mallon Mark","position":1,"cik":"0001763533","reported_name":"Mallon Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-04-03T23:06:33.000Z","date":"2019-04-01","kind":"grant","acquired":true,"shares":423049,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The option, granted as a new Chief Executive Officer award, vests as to 25% of the shares of Class A Common Stock on the first anniversary of January 4, 2019 and 1/48th of the shares of Class A Common Stock vest each month thereafter for the next 36 months."}],"balance_after":423049,"derivative":{"exercise_price":14.02,"expiration_date":"2029-04-01","underlying":"Class A Common Stock","underlying_shares":423049},"source":{"system":"sec-edgar","filing":"0001209191-19-023482","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919119023482/doc4.xml","form_type":"4"}},{"id":3564606,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":129648,"kind":"person","name":"Mallon Mark","position":1,"cik":"0001763533","reported_name":"Mallon Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-04-03T23:06:33.000Z","date":"2019-04-01","kind":"grant","acquired":true,"shares":21203,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation.  In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted to preserve the pre-Separation intrinsic value of the existing Ironwood option award."},{"field":"shares","element":"transactionShares","label":"F3","text":"Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation.  In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted to preserve the pre-Separation intrinsic value of the existing Ironwood option award."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Represents options to purchase Ironwood Class A Common Stock awarded to the reporting person prior to the Separation.  In connection with the Separation, the number of shares subject to this option and the exercise price have been adjusted to preserve the pre-Separation intrinsic value of the existing Ironwood option award."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The option, granted as a new hire award, vests as to 25% of the shares of Class A Common Stock on the first anniversary of January 4, 2019 and 1/48th of the shares of Class A Common Stock vest each month thereafter for the next 36 months."}],"balance_after":192729,"derivative":{"exercise_price":10.97,"expiration_date":"2029-01-09","underlying":"Class A Common Stock","underlying_shares":21203},"source":{"system":"sec-edgar","filing":"0001209191-19-023482","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919119023482/doc4.xml","form_type":"4"}},{"id":3564605,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":129648,"kind":"person","name":"Mallon Mark","position":1,"cik":"0001763533","reported_name":"Mallon Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A Common Stock","published_at":"2019-04-03T23:06:33.000Z","date":"2019-04-01","kind":"grant","acquired":true,"shares":206873,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F2","text":"The restricted stock unit award, granted as a new hire award to the new Chief Executive Officer, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof."}],"balance_after":311409,"source":{"system":"sec-edgar","filing":"0001209191-19-023482","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919119023482/doc4.xml","form_type":"4"}},{"id":3564604,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":129648,"kind":"person","name":"Mallon Mark","position":1,"cik":"0001763533","reported_name":"Mallon Mark","relationship":{"director":true,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Executive Officer"}}],"security":"Class A Common Stock","published_at":"2019-04-03T23:06:33.000Z","date":"2019-04-01","kind":"grant","acquired":true,"shares":11500,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"In connection with the separation (the \"Separation\") of Cyclerion Therapeutics, Inc. from Ironwood Pharmaceuticals, Inc. (\"Ironwood\"), the reporting person received 11,500 restricted stock units as a result of the adjustment of existing Ironwood restricted stock units held by the reporting person prior to the Separation.  The restricted stock units are subject to vesting conditions consistent with the terms of the existing Ironwood restricted stock units held by the reporting person prior to the Separation."}],"balance_after":104536,"source":{"system":"sec-edgar","filing":"0001209191-19-023482","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919119023482/doc4.xml","form_type":"4"}},{"id":3697262,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":129648,"kind":"person","name":"Mallon Mark","position":1,"cik":"0001763533","reported_name":"Mallon Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Senior Advisor"}}],"security":"Employee Stock Option (Right to Buy)","published_at":"2019-01-11T21:13:41.000Z","date":"2019-01-09","kind":"grant","acquired":true,"shares":171526,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The option, granted as a new hire award, vests as to 25% of the shares of Class A Common Stock on the first anniversary of January 4, 2019 and 1/48th of the shares of Class A Common Stock vest each month thereafter for the next 36 months."}],"balance_after":171526,"derivative":{"exercise_price":12.32,"expiration_date":"2029-01-09","underlying":"Class A Common Stock","underlying_shares":171526},"source":{"system":"sec-edgar","filing":"0001209191-19-003409","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919119003409/doc4.xml","form_type":"4"}},{"id":3697261,"issuer":{"id":5213,"kind":"organization","name":"IRONWOOD PHARMACEUTICALS INC","symbol":"IRWD"},"owners":[{"id":129648,"kind":"person","name":"Mallon Mark","position":1,"cik":"0001763533","reported_name":"Mallon Mark","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Executive Senior Advisor"}}],"security":"Class A Common Stock","published_at":"2019-01-11T21:13:41.000Z","date":"2019-01-09","kind":"grant","acquired":true,"shares":93036,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"The restricted stock unit award, granted as a new hire award, vests as to 25% of the shares of Class A Common Stock on each approximate anniversary of the grant thereof."}],"balance_after":93036,"source":{"system":"sec-edgar","filing":"0001209191-19-003409","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1446847/000120919119003409/doc4.xml","form_type":"4"}}]}